<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=3190596&amp;fmt=gif">

Cancer care company Thyme Care garners $60M

Published by on

 

Value-based cancer care platform Thyme Care announced it secured $60 million in Series B funding co-led by Foresite Capital and Town Hall Ventures, bringing its total raise to over $80 million. 

Current investors Andreessen Horowitz BIO + Health, Casdin Capital, Frist Cressey Ventures and AlleyCorp participated in the round. 

Town Hall Ventures' cofounder and general partner David Whelan will join Thyme Care's board of directors, as will Elizabeth Canis, executive advisor at Foresite Capital.


Click here to read the full article. 

Tags:
Back to Blog

Related Articles

ThymeCare-Logo-Wordmark-OffWhite 1

Subscribe to the latest updates:
About Us
Partners
Members
Legal
    Company
    Members
    Partners
    Legal
    © 2024 Thyme Care, Inc. All Rights Reserved. Thyme Care, Inc. and Thyme Care Medical, PLLC. (collectively "Thyme Care", "we", "us" "our") make up the Thyme Care organization. Thyme Care, Inc. provides management support services to Thyme Care Medical, PLLC and non-clinical cancer support services to its members. Thyme Care Medical, PLLC is a health care provider that offers clinical cancer support services to its patients. Thyme Care Medical, PLLC does not direct diagnosis or prescribing of medication for cancer treatment.
    © 2024 Thyme Care, Inc. All Rights Reserved. Thyme Care, Inc. and Thyme Care Medical, PLLC. (collectively "Thyme Care", "we", "us" "our") make up the Thyme Care organization. Thyme Care, Inc. provides management support services to Thyme Care Medical, PLLC and non-clinical cancer support services to its members. Thyme Care Medical, PLLC is a health care provider that offers clinical cancer support services to its patients. Thyme Care Medical, PLLC does not direct diagnosis or prescribing of medication for cancer treatment.